B7273
Bezafibrate
≥98%, peroxisome proliferator-activated receptor agonist, solid
Synonym(s):
2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H20ClNO4
CAS Number:
Molecular Weight:
361.82
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
255-567-9
MDL number:
Product Name
Bezafibrate, ≥98%, solid
Quality Level
assay
≥98%
form
solid
solubility
DMF: soluble, deionized water: insoluble, methanol: soluble
originator
Roche
SMILES string
CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O
InChI
1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
InChI key
IIBYAHWJQTYFKB-UHFFFAOYSA-N
Gene Information
human ... HBA2(3040), PPARA(5465), PPARD(5467), PPARG(5468)
mouse ... Ppara(19013), Ppard(19015), Pparg(19016)
Application
Bezafibrate has been used:
- a supplement in the standard diet (SD) for mice to study its effect on diabetes
- to evaluate its effect on hepatitis C virus (HCV) assembly and secretion
- to evaluate its effect on gonadal steroidogenesis and spermatogenesis of zebrafish and also used as standard for HPLC
Biochem/physiol Actions
Bezafibrate has the ability to repress HCV assembly and secretion. It is used to treat dyslipidemia.
Bezafibrate is a peroxisome proliferator-activated receptor agonist for PPARα, PPARδ, and PPARγ. Lipoprotein lipase (LPL) activator.
The peroxisome proliferator-activated receptor (PPAR) is a member of the steroid nuclear receptor superfamily. Bezafibrate is a peroxisome proliferator-activated receptor agonist for PPARα, PPARδ, and PPARγ. Lipoprotein lipase (LPL) activator.
PPARgamma agonists, including Bezafibrate, have beneficial effects in the suppression of the inflammatory response during RSV infection and therefore might have clinical efficacy in the course of severe RSV-infection.
PPARgamma agonists, including Bezafibrate, have beneficial effects in the suppression of the inflammatory response during RSV infection and therefore might have clinical efficacy in the course of severe RSV-infection.
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under Bezafibrate
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice
Franko A, et al.
Molecular Metabolism, 6(3), 256-266 (2017)
Marc Engelen et al.
PloS one, 7(7), e41013-e41013 (2012-08-23)
X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene and is characterized by impaired beta-oxidation of very-long-chain fatty acids (VLCFA) and subsequent VLCFA accumulation in tissues. In adulthood X-ALD most commonly manifests as a gradually progressive myelopathy, (adrenomyeloneuropathy;
Bezafibrate improves insulin sensitivity and metabolic flexibility in STZ-induced diabetic mice
Franko A, et al.
Diabetes, 65(9), 2540-2552 (2016)